Loading...
•
Sep 30, 2022
Editas Q3 2022 Earnings Report
Editas Medicine reported a net loss for Q3 2022 and provided updates on its clinical programs.
Key Takeaways
Editas Medicine reported a net loss of $55.7 million for the third quarter of 2022, compared to a net loss of $39.1 million for the same period in 2021. The company is progressing with its clinical trials for EDIT-301 and EDIT-101 and expects to provide clinical updates in the near future. Cash, cash equivalents, and marketable securities were $478.5 million as of September 30, 2022.
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease.
On track to announce initial preliminary clinical data from RUBY trial by year-end.
Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT.
Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month.
Revenue by Segment
Forward Guidance
Editas Medicine expects that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditures into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...